Tumor Necrosis Factor-&agr; Augments Tumor Effects in Isolated Hepatic Perfusion With Melphalan in a Rat Sarcoma Model

Isolated hepatic perfusion (IHP) is an attractive approach to treating nonresectable liver tumors, because the effects of systemic chemotherapy are poor and its application is hampered by severe general toxicity. In clinical and experimental settings, the efficacy of isolated limb perfusion (ILP) with tumor necrosis factor-&agr; (TNF&agr;) in combination with melphalan to treat melanoma in transit and soft-tissue sarcoma has been well established. In an ILP model in rats, the authors previously observed synergistic anti-tumor effects of TNF and melphalan on BN 175 soft-tissue sarcoma extremity tumors. The aim of the current study was to determine whether similar synergy in anti-tumor effects could be achieved by treating experimental BN 175 soft-tissue sarcoma liver tumors by IHP using these agents. The authors found that IHP with TNF and melphalan resulted in a dramatic increase in regional concentrations of perfused agents with virtually no concomitant systemic leakage. Isolated hepatic perfusion with only carrier solution resulted in a significantly diminished growth rate of BN 175 liver tumors compared with the growth rate of tumors in nonperfused rats. Perfusion with melphalan alone resulted in minimal anti-tumor effects. Perfusion with only TNF had a slight growth-stimulatory effect on the BN 175 liver tumors, but no negative effects on tumor growth were observed. When TNF was added to melphalan, a dramatic anti-tumor effect was observed. Thus, as in the rat ILP setting, the anti-tumor effect is augmented when TNF is added to IHP with melphalan to treat BN 175 soft-tissue sarcoma tumor-bearing rats. Strikingly, the tumor response was potentiated at relatively low concentrations of TNF compared with concentrations that elicited synergy with melphalan in ILP.

[1]  M. Oudkerk,et al.  Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. , 2000, Hepato-gastroenterology.

[2]  A. Eggermont,et al.  Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion , 2000, British Journal of Cancer.

[3]  A. Eggermont,et al.  TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects , 2000, British Journal of Cancer.

[4]  I. B. Borel Rinkes,et al.  Acute‐phase response patterns in isolated hepatic perfusion with tumour necrosis factor α (TNF‐α) and melphalan in patients with colorectal liver metastases , 1999 .

[5]  T. Scherstén,et al.  Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  A. Eggermont,et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.

[7]  A. Eggermont,et al.  In vivo isolated kidney perfusion with tumour necrosis factor α (TNF-α) in tumour-bearing rats , 1999, British Journal of Cancer.

[8]  A. Eggermont,et al.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. , 1998, Annals of surgery.

[9]  H. Alexander,et al.  Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  P. Flemming,et al.  First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. , 1998, Surgery.

[11]  K. Tracey,et al.  The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Kuppen,et al.  Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? , 1998, Seminars in surgical oncology.

[13]  D. Fraker,et al.  Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Bieler,et al.  Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ , 1998, Nature Medicine.

[15]  G. Bieler,et al.  Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. , 1998, Nature medicine.

[16]  I. B. Borel Rinkes,et al.  Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[17]  I. B. Borel Rinkes,et al.  Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. , 1997, British Journal of Cancer.

[18]  I. B. Borel Rinkes,et al.  Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. , 1997, British Journal of Cancer.

[19]  C. Wiltschke,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[21]  A. Eggermont,et al.  Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. , 1996, British Journal of Cancer.

[22]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Eggermont,et al.  Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat , 1996, The British journal of surgery.

[24]  K. Tracey,et al.  Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone , 1996, The Journal of experimental medicine.

[25]  M. Buyse.  Meta-analysis group in cancer: reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer , 1996 .

[26]  A. Eggermont,et al.  VWF release and platelet aggregation in human melanoma after perfusion with TNFα , 1995, The Journal of pathology.

[27]  D. Fraker,et al.  Use of tumor necrosis factor in isolated hepatic perfusion. , 1994, Circulatory shock.

[28]  A. Bengtsson,et al.  Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. , 1994, Surgical oncology.

[29]  A. Eggermont,et al.  Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). , 1994, International journal of cancer.

[30]  H. Northoff,et al.  Production of tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in the perfused rat liver. , 1993, European cytokine network.

[31]  P. Rougier,et al.  Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S D Prionas,et al.  Dual role of tumor necrosis factor-alpha in angiogenesis. , 1992, The American journal of pathology.

[33]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Kuppen,et al.  Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion. , 1991, British Journal of Cancer.

[35]  W. Buurman,et al.  Evaluation of measurement of human TNF in plasma by ELISA. , 1991, Lymphokine and cytokine research.

[36]  C. V. D. van de Velde,et al.  Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. , 1991, Cancer research.

[37]  P. Kuppen,et al.  A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. , 1990, British Journal of Cancer.

[38]  P D Schneider,et al.  A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. , 1987, Annals of surgery.

[39]  D. Newell,et al.  In pursuit of evidence based integrated care , 1987, British Journal of Cancer.

[40]  M. Rosenblum,et al.  Phase I study of recombinant tumor necrosis factor in cancer patients. , 1987, Cancer research.

[41]  C. V. D. van de Velde,et al.  A successful technique of in vivo isolated liver perfusion in pigs. , 1986, The Journal of surgical research.

[42]  M. E. Carver,et al.  Serum-free in vitro bioassay for the detection of tumor necrosis factor. , 1986, Journal of immunological methods.

[43]  E. Quebbeman,et al.  Tumoricidal effects and patient survival after hyperthermic liver perfusion. , 1986, Archives of surgery.

[44]  W. Lierse,et al.  Vaskularisation von Lebermetastasen: eine korrosionsanatomische Studie , 1986 .

[45]  U. Almagro,et al.  A technique for isolation perfusion of the canine liver with survival. , 1983, The Journal of surgical research.

[46]  J. Tonn,et al.  [Isolated liver perfusion with 5-fluorouracil (5-FU) in the human]. , 1982, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[47]  D. Levin,et al.  A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. , 1978, Cancer research.